Production and immunogenicity of chimaeric human papillomavirus-like particle vaccines

Human papillomavirus (HPV) infection, specifically with oncogenic types, has been implicated in effectively all cervical cancer cases. Cervical cancer is a global health burden, especially in the developing world. Up to 18 types of HPV are considered oncogenic, of which HPV -16 and -18 cause 70% of cervical cancer cases worldwide. Two vaccines are available on the market: Gardasil(R), targeted against HPV -16, -18; -6 and -11, and Cervarix(TM), against -16 and -18. Both vaccines are based on the L1 capsid proteins of the types they are targeted to and are efficient, pro- phylactic, typespecific vaccines. However, two problems remain: they do not protect against nonvaccine types, that may cause a significant proportion of cancers specifically in African and HIV- positive populations, and they cannot be used to treat existing infections. We designed eight different chimaeric vaccines.

Grantor dc:publisher.institution

Department of Molecular and Cell Biology

Year dc:date.issued

2010

Author dc:creator

• Burger, Marieta

Advisors dc:contributor.advisor

• Rybicki, Ed
• Hitzeroth, Inga

Language dc:language.iso

eng

Handle dc:identifier.uri

http://hdl.handle.net/11427/12377

OAI identifier oai:identifier

oai:open.uct.ac.za:11427/12377